NasdaqGS:LEGNBiotechs
How New Long-Term CARVYKTI Safety Data At Legend Biotech (LEGN) Has Changed Its Investment Story
Earlier this month, Legend Biotech reported new long-term clinical and translational data for its CARVYKTI CAR-T therapy in relapsed or refractory multiple myeloma, including updated efficacy and safety findings from the CARTITUDE-1 and CARTITUDE-4 trials.
The disclosure that over half of treated patients received the immune-modulating drug tocilizumab, alongside reports of neurologic toxicity with parkinsonism, adds important context to CARVYKTI's real-world risk–benefit profile and...